Clinical Trials Browser

Lymphoma, Follicular, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05937269 2025-09-09

Assessing Impact of Early Physiotherapy on Lymphatic Dysfunction in Head and Neck Cancer Survivorship

Phase 1 Enrolling by invitation

20 enrolled

Head & Neck

Head and Neck Neoplasms

NCT06827782 2025-08-15

Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma

Phase 1 Enrolling by invitation

42 enrolled

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07053904 2025-07-08

Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors

Phase 1 Enrolling by invitation

54 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT06896110 2025-06-26

Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma

Phase 1 Enrolling by invitation

34 enrolled

CNS

Astrocytoma, Glioblastoma

Clinical Trials

VascuLens RCT

J21112LINKED

Second Window Indocyanine Green for All Nervous System Tumors

A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors

Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

DLIT-AML

Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors

Clinical Trial to Treat Stage IV Cancer Patients

JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study

CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

Assessing Impact of Early Physiotherapy on Lymphatic Dysfunction in Head and Neck Cancer Survivorship

Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma

Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors

Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma